Pharmaco-genomics/-genetics and breast/ovarian cancer
~ Genetics of Breast & Ovarian Cancer

List was last updated on Oct 7, 2019 @ 3:44 am.


    • Available and emerging molecular markers in the clinical management of breast cancer.
    • Giridhar KV, Liu MC.
    • Expert Rev Mol Diagn. 2019 Sep 9. doi: 10.1080/14737159.2019.1664901. [Epub ahead of print]
    • Review
    • Association of a Pathway-Specific Genetic Risk Score With Risk of Radiation-Associated Contralateral Breast Cancer.
    • Watt GP, Reiner AS, Smith SA, Stram DO, Capanu M, Malone KE, Lynch CF, John EM, Knight JA, Mellemkjær L, Bernstein L, Brooks JD, Woods M, Liang X, Haile RW, Riaz N, Conti DV, Robson M, Duggan D, Boice JD Jr, Shore RE, Tischkowitz M, Orlow I, Thomas DC, Concannon P, Bernstein JL.
    • JAMA Netw Open. 2019 Sep 4;2(9):e1912259. doi: 10.1001/jamanetworkopen.2019.12259.
    • Aspirin Treatment Effect and Association with PIK3CA Mutation in Breast Cancer: A Biomarker Analysis.
    • Zhou Y, Simmons J, Jordan CD, Sonbol MB, Maihle N, Tang SC.
    • Clin Breast Cancer. 2019 May 18. pii: S1526-8209(19)30066-7. doi: 10.1016/j.clbc.2019.05.004. [Epub ahead of print]
    • ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
    • Mesquita KA, Alabdullah M, Griffin M, Toss MS, Fatah TMAA, Alblihy A, Moseley P, Chan SYT, Rakha EA, Madhusudan S.
    • Gynecol Oncol. 2019 May;153(2):416-424. doi: 10.1016/j.ygyno.2019.02.014. Epub 2019 Feb 20.
    • A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.
    • Ciruelos E, Apellániz-Ruiz M, Cantos B, Martinez-Jáñez N, Bueno-Muiño C, Echarri MJ, Enrech S, Guerra JA, Manso L, Pascual T, Dominguez C, Gonzalo JF, Sanz JL, Rodriguez-Antona C, Sepúlveda JM.
    • Oncologist. 2019 Apr 25. pii: theoncologist.2017-0664. doi: 10.1634/theoncologist.2017-0664. [Epub ahead of print]
    • 4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.
    • Wang G, Qin S, Zayas J, Ingle JN, Liu M, Weinshilboum RM, Shen K, Wang L.
    • Breast Cancer Res Treat. 2019 Apr 1. doi: 10.1007/s10549-019-05194-z. [Epub ahead of print]
    • A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study.
    • Gagno S, D'Andrea MR, Mansutti M, Zanusso C, Puglisi F, Dreussi E, Montico M, Biason P, Cecchin E, Iacono D, Russo S, Cinausero M, Saracchini S, Gasparini G, Sartori D, Bari M, Collovà E, Meo R, Merkabaoui G, Spagnoletti I, Pellegrino A, Gianni L, Sandri P, Cretella E, Vattemi E, Rocca A, Serra P, Fabbri MA, Benedetti G, Foghini L, Medici M, Basso U, Amoroso V, Riccardi F, Baldelli AM, Clerico M, Bonura S, Saggia C, Innocenti F, Toffoli G.
    • Clin Breast Cancer. 2019 Apr;19(2):137-145.e4. doi: 10.1016/j.clbc.2018.11.009. Epub 2018 Nov 24.
    • The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin.
    • Cuyàs E, Buxó M, Ferri Iglesias MJ, Verdura S, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Joven J, Brunet J, López-Bonet E, Garcia M, Saidani S, Queralt Moles X, Martin-Castillo B, Menendez JA.
    • Front Oncol. 2019 Mar 28;9:193. doi: 10.3389/fonc.2019.00193. eCollection 2019.
    • PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
    • Chia SKL, Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Kim SB, Jakobsen EH, Harvey V, Robert N, Smith J 2nd, Harker G, Zhang B, Eli LD, Ye Y, Lalani AS, Buyse M, Chan A.
    • Breast Cancer Res. 2019 Mar 11;21(1):39. doi: 10.1186/s13058-019-1115-2.
    • CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.
    • Brooks JD, Comen EA, Reiner AS, Orlow I, Leong SF, Liang X, Mellemkjær L, Knight JA, Lynch CF, John EM, Bernstein L, Woods M, Doody DR; WECARE Study collaborative group, Malone KE, Bernstein JL.
    • Breast Cancer Res. 2018 Dec 10;20(1):149. doi: 10.1186/s13058-018-1083-y.
    • Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China.
    • Lan B, Ma F, Chen S, Wang W, Li Q, Fan Y, Luo Y, Cai R, Wang J, Yuan P, Zhang P, Li Q, Xu B.
    • Int J Cancer. 2018 Nov 15;143(10):2499-2504. doi: 10.1002/ijc.31639. Epub 2018 Sep 19.
    • Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10 T/T genotype breast cancer patients in China.
    • Lan B, Ma F, Chen S, Wang W, Li Q, Fan Y, Luo Y, Cai R, Wang J, Yuan P, Zhang P, Li Q, Xu B.
    • Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31639. [Epub ahead of print]
    • The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
    • Lan B, Ma F, Zhai X, Li Q, Chen S, Wang J, Fan Y, Luo Y, Cai R, Yuan P, Zhang P, Li Q, Xu B.
    • Int J Cancer. 2018 Jul 1;143(1):184-189. doi: 10.1002/ijc.31291. Epub 2018 Feb 16.
    • Study on the Mechanism of Cell Cycle Checkpoint Kinase 2 (CHEK2) Gene Dysfunction in Chemotherapeutic Drug Resistance of Triple Negative Breast Cancer Cells.
    • Luo L, Gao W, Wang J, Wang D, Peng X, Jia Z, Jiang Y, Li G, Tang D, Wang Y.
    • Med Sci Monit. 2018 May 15;24:3176-3183. doi: 10.12659/MSM.907256.
    • A8 Pharmacogenetic models of adverse reactions to FAC chemotherapy in breast cancer patients.
    • Tęcza K, Pamuła-Piłat J, Grzybowska E.
    • Hered Cancer Clin Pract. 2018 Feb 28;16(Suppl 1):A8. Meeting abstracts from Clinical Genetics of Cancer 2017; Szczecin, Poland. 21-22 September 2017. doi: 10.1186/s13053-018-0087-z.
    • Conference abstract
    • A9 3’utr polymorphisms of the XMETS genes and its potential effects on the FAC chemotherapy in breast cancer patients.
    • Pamuła-Piłat J, Tęcza K, Mazur M, Grzybowska E.
    • Hered Cancer Clin Pract. 2018 Feb 28;16(Suppl 1):A9. Meeting abstracts from Clinical Genetics of Cancer 2017; Szczecin, Poland. 21-22 September 2017. doi: 10.1186/s13053-018-0087-z.
    • Conference abstract
    • Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.
    • Tecza K, Pamula-Pilat J, Lanuszewska J, Butkiewicz D, Grzybowska E.
    • Oncotarget. 2018 Jan 10;9(10):9114-9136. doi: 10.18632/oncotarget.24148. eCollection 2018 Feb 6.
    • Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.
    • van Rossum AGJ, Kok M, McCool D, Opdam M, Miltenburg NC, Mandjes IAM, van Leeuwen-Stok E, Imholz ALT, Portielje JEA, Bos MMEM, van Bochove A, van Werkhoven E, Schmidt MK, Oosterkamp HM, Linn SC.
    • Oncotarget. 2017 Nov 27;8(69):113531-113542. doi: 10.18632/oncotarget.22697. eCollection 2017 Dec 26.
    • SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ERα-positive breast cancer through regulation of BRCA1.
    • Cairns J, Ingle JN, Wickerham LD, Weinshilboum R, Liu M, Wang L.
    • PLoS Genet. 2017 Oct 2;13(10):e1007031. doi: 10.1371/journal.pgen.1007031. eCollection 2017 Oct.
    • Germline Genetic Variants with Implications for Disease Risk and Therapeutic Outcomes.
    • Pasternak AL, Ward KM, Luzum JA, Ellingrod VL, Hertz DL.
    • Physiol Genomics. 2017 Oct 1;49(10):567-581. doi: 10.1152/physiolgenomics.00035.2017. Epub 2017 Sep 8.
    • Review
    • Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes.
    • Liu D, Ho MF, Schaid DJ, Scherer SE, Kalari K, Liu M, Biernacka J, Yee V, Evans J, Carlson E, Goetz MP, Kubo M, Wickerham DL, Wang L, Ingle JN, Weinshilboum RM.
    • NPJ Breast Cancer. 2017 Aug 21;3:30. doi: 10.1038/s41523-017-0036-4. eCollection 2017.
    • Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.
    • Qin S, Ingle JN, Liu M, Yu J, Wickerham DL, Kubo M, Weinshilboum RM, Wang L.
    • Breast Cancer Res. 2017 Aug 18;19(1):95. doi: 10.1186/s13058-017-0890-x.
    • Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
    • Pascual T, Apellániz-Ruiz M, Pernaut C, Cueto-Felgueroso C, Villalba P, Álvarez C, Manso L, Inglada-Pérez L, Robledo M, Rodríguez-Antona C, Ciruelos E.
    • PLoS One. 2017 Jul 20;12(7):e0180192. doi: 10.1371/journal.pone.0180192. eCollection 2017.
    • Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.
    • Meißner T, Mark A, Williams C, Berdel WE, Wiebe S, Kerkhoff A, Wardelmann E, Gaiser T, Müller-Tidow C, Rosenstiel P, Arnold N, Leyland-Jones B, Franke A, Stanulla M, Forster M.
    • Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4). pii: a001677. doi: 10.1101/mcs.a001677. Print 2017 Jul.
    • SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.
    • Dudenkov TM, Ingle JN, Buzdar AU, Robson ME, Kubo M, Ibrahim-Zada I, Batzler A, Jenkins GD, Pietrzak TL, Carlson EE, Barman P, Goetz MP, Northfelt DW, Moreno-Aspita A, Williard CV, Kalari KR, Nakamura Y, Wang L, Weinshilboum RM.
    • Breast Cancer Res Treat. 2017 Jul;164(1):189-199. doi: 10.1007/s10549-017-4243-3. Epub 2017 Apr 20.
    • Comprehensive strategy for the design of precision drugs and identification of genetic signature behind proneness of the disease-a pharmacogenomic approach.
    • Iyer PM, Karthikeyan S, Sanjay Kumar P, Krishnan Namboori PK.
    • Funct Integr Genomics. 2017 Jul;17(4):375-385. doi: 10.1007/s10142-017-0559-7. Epub 2017 May 3.
    • Review
    • Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?
    • Partridge AH, Sepucha K, O'Neill A, Miller KD, Baker E, Dang CT, Northfelt DW, Sledge GW, Schneider BP.
    • Breast Cancer Res Treat. 2017 Jun 23. doi: 10.1007/s10549-017-4338-x. [Epub ahead of print]
    • Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study.
    • Zembutsu H, Nakamura S, Akashi-Tanaka S, Kuwayama T, Watanabe C, Takamaru T, Takei H, Ishikawa T, Miyahara K, Matsumoto H, Hasegawa Y, Kutomi G, Shima H, Satomi F, Okazaki M, Zaha H, Onomura M, Matsukata A, Sagara Y, Baba S, Yamada A, Shimada K, Shimizu D, Tsugawa K, Shimo A, Tan EY, Hartman M, Chan CW, Lee SC, Nakamura Y.
    • Clin Cancer Res. 2017 Apr 15;23(8):2019-2026. doi: 10.1158/1078-0432.CCR-16-1779. Epub 2016 Oct 19.
    • Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.
    • Gavin PG, Song N, Kim SR, Lipchik C, Johnson NL, Bandos H, Finnigan M, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Wickerham DL, Geyer CE Jr, Jeong JH, Costantino JP, Wolmark N, Paik S, Pogue-Geile KL.
    • JAMA Oncol. 2017 Mar 1;3(3):335-341. doi: 10.1001/jamaoncol.2016.4884.
    • Predictive Value of FcR Polymorphisms: A Further Step on the Long and Winding Road to Application.
    • Dolcetti R.
    • JAMA Oncol. 2017 Mar 1;3(3):342-343. doi: 10.1001/jamaoncol.2016.4905.
    • Commentary
    • Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor Olaparib by a dominant negative effect.
    • Vaclová T, Woods NT, Megías D, Gomez-Lopez S, Setién F, García Bueno JM, Macías JA, Barroso A, Urioste M, Esteller M, Monteiro AN, Benítez J, Osorio A.
    • Hum Mol Genet. 2016 Dec 15;25(24):5287-5299. doi: 10.1093/hmg/ddw343.
    • Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.
    • Ingle JN, Xie F, Ellis MJ, Goss PE, Shepherd LE, Chapman JW, Chen BE, Kubo M, Furukawa Y, Momozawa Y, Stearns V, Pritchard KI, Barman P, Carlson EE, Goetz MP, Weinshilboum RM, Kalari KR, Wang L.
    • Cancer Res. 2016 Dec 1;76(23):7012-7023. Epub 2016 Oct 10.
    • The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.
    • Guffanti F, Fruscio R, Rulli E, Damia G.
    • Sci Rep. 2016 Dec 1;6:38142. doi: 10.1038/srep38142.
    • GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis.
    • Kong X, Li Z, Li X.
    • Cancer Chemother Pharmacol. 2016 Dec;78(6):1163-1173. Epub 2016 Oct 26.
    • Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.
    • Spugnesi L, Gabriele M, Scarpitta R, Tancredi M, Maresca L, Gambino G, Collavoli A, Aretini P, Bertolini I, Salvadori B, Landucci E, Fontana A, Rossetti E, Roncella M, Naccarato GA, Caligo MA.
    • Genes Chromosomes Cancer. 2016 Dec;55(12):915-924. doi: 10.1002/gcc.22389. Epub 2016 Jul 26.
    • Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.
    • Lam SW, Frederiks CN, van der Straaten T, Honkoop AH, Guchelaar HJ, Boven E.
    • Br J Cancer. 2016 Nov 22;115(11):1335-1342. doi: 10.1038/bjc.2016.326. Epub 2016 Oct 13.
    • Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy.
    • Goetz MP, Ratain M, Ingle JN.
    • J Clin Oncol. 2016 Nov 10;34(32):3944-3945. doi: 10.1200/JCO.2016.68.5214.
    • Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.
    • Johansson H, Gray KP, Pagani O, Regan MM, Viale G, Aristarco V, Macis D, Puccio A, Roux S, Maibach R, Colleoni M, Rabaglio M, Price KN, Coates AS, Gelber RD, Goldhirsch A, Kammler R, Bonanni B, Walley BA; the TEXT principal investigators.
    • Breast Cancer Res. 2016 Nov 8;18(1):110.
    • Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.
    • Gavin PG, Song N, Kim SR, Lipchik C, Johnson NL, Bandos H, Finnigan M, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Wickerham DL, Geyer CE Jr, Jeong JH, Costantino JP, Wolmark N, Paik S, Pogue-Geile KL.
    • JAMA Oncol. 2016 Nov 3. doi: 10.1001/jamaoncol.2016.4884. [Epub ahead of print]
    • Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.
    • Pulford DJ, Harter P, Floquet A, Barrett C, Suh DH, Friedlander M, Arranz JA, Hasegawa K, Tada H, Vuylsteke P, Mirza MR, Donadello N, Scambia G, Johnson T, Cox C, Chan JK, Imhof M, Herzog TJ, Calvert P, Wimberger P, Berton-Rigaud D, Lim MC, Elser G, Xu CF, du Bois A.
    • BMC Med Ethics. 2016 Oct 21;17(1):63.
    • Genomic Disparities in Breast Cancer Among Latinas.
    • Lynce F, Graves KD, Jandorf L, Ricker C, Castro E, Moreno L, Augusto B, Fejerman L, Vadaparampil ST.
    • Cancer Control. 2016 Oct;23(4):359-372.
    • National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China.
    • Lin G, Zhang K, Yi L, Han Y, Xie J, Li J.
    • PLoS One. 2016 Sep 7;11(9):e0162361. doi: 10.1371/journal.pone.0162361. eCollection 2016.
    • Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.
    • Dimitrova D, Ruscito I, Olek S, Richter , Hellwag A, Türbachova I, Woopen H, Baron U, Braicu EI, Sehouli J.
    • Tumour Biol. 2016 Sep;37(9):12329-12337. doi: 10.1007/s13277-016-5109-8. Epub 2016 Jun 14.
    • Note of the methodological flaws in the paper entitled "GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis".
    • Qiu M, Wu X, Qu X.
    • Tumour Biol. 2016 Sep;37(9):12897-12899. Epub 2016 Jul 21.
    • Commentary

    Review, Meta-Analysis

    GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis.

    • Tamoxifen precipitation of familial hypertriglyceridaemia: a rare cause of acute pancreatitis.
    • Wadood A, Chesner R, Mirza M, Zaman S.
    • BMJ Case Rep. 2016 Aug 3;2016. pii: bcr2016214837. doi: 10.1136/bcr-2016-214837.
    • Case report
    • A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.
    • Johansson H, Gandini S, Serrano D, Gjerde J, Lattanzi M, Macis D, Guerrieri-Gonzaga A, Aristarco V, Mellgren G, Lien E, DeCensi A, Bonanni B.
    • Breast Cancer Res Treat. 2016 Aug;159(1):97-108. doi: 10.1007/s10549-016-3932-7. Epub 2016 Aug 2.
    • Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials.
    • Brentnall AR, Cuzick J, Byers H, Segal C, Reuter C, Detre S, Sestak I, Howell A, Powles TJ, Newman WG, Dowsett M.
    • Breast Cancer Res Treat. 2016 Aug;158(3):591-6. doi: 10.1007/s10549-016-3885-x. Epub 2016 Jul 11.
    • Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues.
    • Ju LL, Zhao CY, Ye KF, Yang H, Zhang J.
    • Eur Rev Med Pharmacol Sci. 2016 May;20(10):1993-2003.
    • Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.
    • Johnson N, De Ieso P, Migliorini G, Orr N, Broderick P, Catovsky D, Matakidou A, Eisen T, Goldsmith C, Dudbridge F, Peto J, Dos-Santos-Silva I, Ashworth A, Ross G, Houlston RS, Fletcher O.
    • Cancer Res. 2016 Mar 15;76(6):1485-93. doi: 10.1158/0008-5472.CAN-15-1410.
    • Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.
    • Santa-Maria CA, Blackford A, Nguyen AT, Skaar TC, Philips S, Oesterreich S, Rae JM, Desta Z, Robarge J, Henry NL, Storniolo AM, Hayes DF, Blumenthal RS, Ouyang P, Post WS, Flockhart DA, Stearns V; Consortium on Breast Cancer Pharmacogenomics (COBRA).
    • Clin Cancer Res. 2016 Mar 15;22(6):1395-402. doi: 10.1158/1078-0432.CCR-15-1213. Epub 2015 Oct 13.
    • Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer.
    • French JD, Johnatty SE, Lu Y, Beesley J, Gao B, Kalimutho M, Henderson MJ, Russell AJ, Kar S, Chen X, Hillman KM, Kaufmann S, Sivakumaran H, O'Reilly M, Wang C, Korbie DJ; Australian Ovarian Cancer Study Group; Australian Ovarian Cancer Study, Lambrechts D, Despierre E, Van Nieuwenhuysen E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching PA, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Pisterer J, Hillemanns P, Nakanishi T, Yatabe Y, Goodman MT, Lurie G, Matsuno RK, Thompson PJ, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan JM, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut JM, Iversen E, Weber RP, Brennan D, Berchuck A, Pharoah P, Harnett P, Norris MD, Haber M, Goode EL, Lee JS, Khanna KK, Meyer KB, Chenevix-Trench G, deFazio A, Edwards SL, MacGregor S, On Behalf Of The Ovarian Cancer Association Consortium.
    • Oncotarget. 2016 Feb 9;7(6):6353-68. doi: 10.18632/oncotarget.7047.
    • STAT3 polymorphisms may predict an unfavorable response to first-line platinum-based therapy for women with advanced serous epithelial ovarian cancer.
    • Permuth-Wey J, Fulp WJ, Reid BM, Chen Z, Georgeades C, Cheng JQ, Magliocco A, Chen DT, Lancaster JM.
    • Int J Cancer. 2016 Feb 1;138(3):612-9. doi: 10.1002/ijc.29799. Epub 2015 Aug 28.
    • High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer.
    • Schouten PC, Vollebergh MA, Opdam M, Jonkers M, Loden M, Wesseling J, Hauptmann M, Linn SC.
    • Mol Cancer Ther. 2016 Jan;15(1):190-8. doi: 10.1158/1535-7163.MCT-15-0470. Epub 2015 Dec 4.
    • GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis.
    • Hu XY, Huang XY, Ma J, Zuo Y, Luo NB, Lai SL, Su DK.
    • Tumour Biol. 2016 Jan;37(1):151-62. doi: 10.1007/s13277-015-4401-3. Epub 2015 Nov 14.
    • Review, Meta-Analysis

    Commentary

    Note of the methodological flaws in the paper entitled "GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis".

    • Pharmacogenetic Predictors of Response.
    • Hertz DL, Rae JM.
    • Adv Exp Med Biol. 2016;882:191-215. doi: 10.1007/978-3-319-22909-6_8.
    • Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.
    • Hein A, Lambrechts D, von Minckwitz G, Häberle L, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, Gerber B, Dan Costa S, Blohmer JU, Schwedler K, Kittel K, Fehm T, Kunz G, Beckmann MW, Ekici AB, Hanusch C, Huober J, Liedtke C, Mau C, Moisse M, Müller V, Nekljudova V, Peuteman G, Rack B, Rübner M, Van Brussel T, Wang L, Weinshilboum RM, Loibl S, Fasching PA.
    • Int J Cancer. 2015 Dec 15;137(12):2981-8. doi: 10.1002/ijc.29656. Epub 2015 Jul 6.
    • Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium.
    • Johnatty SE, Tyrer JP, Kar S, Beesley J, Lu Y, Gao B, Fasching PA, Hein A, Ekici AB, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambrechts S, Rossing MA, Doherty JA, Chang-Claude J, Modugno F, Ness RB, Moysich KB, Levine DA, Kiemeney LA, Massuger LF, Gronwald J, Lubiński J, Jakubowska A, Cybulski C, Brinton L, Lissowska J, Wentzensen N, Song H, Rhenius V, Campbell I, Eccles D, Sieh W, Whittemore AS, McGuire V, Rothstein JH, Sutphen R, Anton-Culver H, Ziogas A, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Pearce CL, Pike MC, Stram DO, Wu AH, Kupryjanczyk J, Dansonka-Mieszkowska A, Rzepecka IK, Spiewankiewicz B, Goodman MT, Wilkens LR, Carney ME, Thompson PJ, Heitz F, du Bois A, Schwaab I, Harter P, Pisterer J, Hillemanns P; AGO Study Group, Karlan BY, Walsh C, Lester J, Orsulic S, Winham SJ, Earp M, Larson MC, Fogarty ZC, Høgdall E, Jensen A, Kjaer SK, Fridley BL, Cunningham JM, Vierkant RA, Schildkraut JM, Iversen ES, Terry KL, Cramer DW, Bandera EV, Orlow I, Pejovic T, Bean Y, Høgdall C, Lundvall L, McNeish I, Paul J, Carty K, Siddiqui N, Glasspool R, Sellers T, Kennedy C, Chiew YE, Berchuck A, MacGregor S, Pharoah PD, Goode EL, deFazio A, Webb PM, Chenevix-Trench G; Australian Ovarian Cancer Study Group.
    • Clin Cancer Res. 2015 Dec 1;21(23):5264-76. doi: 10.1158/1078-0432.CCR-15-0632. Epub 2015 Jul 7.
    • Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
    • Oesterreich S, Henry NL, Kidwell KM, Van Poznak CH, Skaar TC, Dantzer J, Li L, Hangartner TN, Peacock M, Nguyen AT, Rae JM, Desta Z, Philips S, Storniolo AM, Stearns V, Hayes DF, Flockhart DA.
    • Breast Cancer Res Treat. 2015 Nov;154(2):263-73. doi: 10.1007/s10549-015-3608-8. Epub 2015 Nov 4.
    • Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.
    • Lips EH, Michaut M, Hoogstraat M, Mulder L, Besselink NJ, Koudijs MJ, Cuppen E, Voest EE, Bernards R, Nederlof PM, Wesseling J, Rodenhuis S, Wessels LF; Center for Personalized Cancer Treatment.
    • Breast Cancer Res. 2015 Oct 3;17(1):134. doi: 10.1186/s13058-015-0642-8.
    • Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer.
    • Yuan H, Chen J, Liu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Clin Cancer Res. 2015 Oct 1;21(19):4365-72. doi: 10.1158/1078-0432.CCR-14-3354. Epub 2015 May 15.
    • CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
    • Dezentjé VO, Opdam FL, Gelderblom H, Hartigh den J, Van der Straaten T, Vree R, Maartense E, Smorenburg CH, Putter H, Dieudonné AS, Neven P, Van de Velde CJ, Nortier JW, Guchelaar HJ.
    • Breast Cancer Res Treat. 2015 Oct;153(3):583-90. doi: 10.1007/s10549-015-3562-5. Epub 2015 Sep 14.
    • Genetic predictors of chemotherapeutic response in ovarian cancer within a previously associated molecular signature.
    • Newtson A, Salinas E, Leslie K, Gonzalez Bosquet J.
    • Gynecologic Oncology. 2015 Oct;139(1):187. 2015 WAGO ABSTRACTS. doi: 10.1016/j.ygyno.2015.07.042.
    • Conference abstract
    • Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy.
    • Khan S, Fagerholm R, Rafiq S, Tapper W, Aittomäki K, Liu J, Blomqvist C, Eccles D, Nevanlinna H.
    • Clin Cancer Res. 2015 Sep 15;21(18):4086-96. doi: 10.1158/1078-0432.CCR-15-0296. Epub 2015 May 11.
    • High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial.
    • Callens C, Debled M, Delord M, Turbiez-Stalain I, Veyret C, Bièche I, Brain E.
    • Breast Cancer Res Treat. 2015 Sep;153(2):383-9. doi: 10.1007/s10549-015-3552-7. Epub 2015 Aug 29.
    • ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors.
    • Dumont A, Pannier D, Ducoulombier A, Tresch E, Chen J, Kramar A, Révillion F, Peyrat JP, Bonneterre J.
    • Springerplus. 2015 Jul 7;4:327. doi: 10.1186/s40064-015-1053-0. eCollection 2015.
    • Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel-Letter.
    • Apellániz-Ruiz M, Sánchez-Barroso L, Gutiérrez-Gutiérrez G, Sereno M, García-Donás J, Åvall-Lundqvist E, Gréen H, Brøsen K, Bergmann TK, Rodríguez-Antona C.
    • Clin Cancer Res. 2015 Jul 1;21(13):3092-3093. doi: 10.1158/1078-0432.CCR-14-1885.
    • Comment, Letter

    Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.

    Letter

    Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel-Response.

    • Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    • Liu Y, Yasukawa M, Chen K, Hu L, Broaddus RR, Ding L, Mardis ER, Spellman P, Levine DA, Mills GB, Shmulevich I, Sood AK, Zhang W.
    • JAMA Oncol. 2015 Jul 1;1(4):486-494. doi: 10.1001/jamaoncol.2015.1432.

    Comment

    Gynaecological cancer: ADAMTS mutations predict sensitivity to chemotherapy in ovarian cancer.

    • Genetic testing and economic evaluations: a systematic review of the literature.
    • D'Andrea E, Marzuillo C, Pelone F, De Vito C, Villari P.
    • Epidemiol Prev. 2015 Jul-Aug;39(4 Suppl 1):45-50.
    • Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
    • Vulsteke C, Pfeil AM, Maggen C, Schwenkglenks M, Pettengell R, Szucs TD, Lambrechts D, Dieudonné AS, Hatse S, Neven P, Paridaens R, Wildiers H.
    • Breast Cancer Res Treat. 2015 Jul;152(1):67-76. doi: 10.1007/s10549-015-3437-9. Epub 2015 May 28.
    • Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients.
    • Islam MS, Islam MS, Parvin S, Ahmed MU, Bin Sayeed MS, Uddin MM, Hussain SM, Hasnat A.
    • Tumour Biol. 2015 Jul;36(7):5451-7. doi: 10.1007/s13277-015-3211-y. Epub 2015 Feb 13.
    • The RAD51 135G>C polymorphism is related to the effect of adjuvant therapy in early breast cancer.
    • Söderlund Leifler K, Asklid A, Fornander T, Stenmark Askmalm M.
    • J Cancer Res Clin Oncol. 2015 May;141(5):797-804. doi: 10.1007/s00432-014-1859-0. Epub 2014 Oct 30.
    • RE: Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies.
    • Rae JM, Leyland-Jones B, Regan M, Thompson AM.
    • J Natl Cancer Inst. 2015 Mar 26;107(5). pii: djv065. Print 2015 May.
    • DNA repair mutations and outcomes in ovarian cancer--letter.
    • Soslow RA.
    • Clin Cancer Res. 2015 Feb 1;21(3):658. doi: 10.1158/1078-0432.CCR-14-2436.

    Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.

    Comment / Letter

    DNA repair mutations and outcomes in ovarian cancer--response.

    • Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.
    • Goetz MP, Sun JX, Suman VJ, Silva GO, Perou CM, Nakamura Y, Cox NJ, Stephens PJ, Miller VA, Ross JS, Chen D, Safgren SL, Kuffel MJ, Ames MM, Kalari KR, Gomez HL, Gonzalez-Angulo AM, Burgues O, Brauch HB, Ingle JN, Ratain MJ, Yelensky R.
    • J Natl Cancer Inst. 2014 Dec 8 [2015 Feb;];107(2). pii: dju401. doi: 10.1093/jnci/dju401.

    Press: Mayo Clinic: Genotyping errors plague CYP2D6 testing for tamoxifen therapy. (EurekAlert!)

    • Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies.
    • Johnson JA, Hamadeh IS, Langaee TY.
    • J Natl Cancer Inst. 2015 Jan 31 [2015 Feb;];107(2). pii: dju437. doi: 10.1093/jnci/dju437. Print 2015 Feb.
    • Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies.
    • Johnson JA, Hamadeh IS, Langaee TY.
    • J Natl Cancer Inst. 2015 Jan 31;107(2). pii: dju437. Print 2015 Feb.

    Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

    • Pharmacogenetics of FAC chemotherapy side effects in breast cancer patients.
    • Karolina Tecza, Jolanta Pamula-Pilat, Joanna Lanuszewska, Ewa Grzybowska.
    • Hereditary Cancer in Clinical Practice 2015, 13(Suppl 2):A10; Meeting abstracts from the Annual Conference on Hereditary Cancers 2014. doi:10.1186/1897-4287-13-S2-A10
    • Conference Abstract
    • MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen.
    • Tengström M, Mannermaa A, Kosma VM, Soini Y, Hirvonen A, Kataja V.
    • Acta Oncol. 2014 Jun;53(6):769-75. doi: 10.3109/0284186X.2014.892210. Epub 2014 Apr 10.
    • Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer.
    • Yao S, Sucheston LE, Zhao H, Barlow WE, Zirpoli G, Liu S, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, Hayes DF, Ambrosone CB.
    • Pharmacogenomics J. 2014 Jun;14(3):241-7. doi: 10.1038/tpj.2013.32. Epub 2013 Sep 3.
    • Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.
    • Goetz MP, Brauch H, Ratain MJ, Cox NJ, Nakamura Y, Weinshilboum R, Ingle JN.
    • J Natl Cancer Inst. 2014 Apr 3;106(5). pii: dju063. doi: 10.1093/jnci/dju063.

    See PubMed abstract for multiple related items.

    • Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors.
    • Pfeil AM, Vulsteke C, Paridaens R, Dieudonné AS, Pettengell R, Hatse S, Neven P, Lambrechts D, Szucs TD, Schwenkglenks M, Wildiers H.
    • BMC Cancer. 2014 Mar 19;14:201. doi: 10.1186/1471-2407-14-201.
    • Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
    • Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, Swisher EM.
    • Clin Cancer Res. 2014 Feb 1;20(3):764-75. doi: 10.1158/1078-0432.CCR-13-2287. Epub 2013 Nov 15.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: PALB2 and Ovarian Cancer

    Comment, Letter

    DNA repair mutations and outcomes in ovarian cancer--letter.

    Reply, Letter

    DNA repair mutations and outcomes in ovarian cancer--response.

    • Re: CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer.
    • Province MA, Klein TE; International Tamoxifen Pharmacogenomics Consortium.
    • J Natl Cancer Inst. 2014 Feb 1;106(2):djt379. doi: 10.1093/jnci/djt379. Epub 2014 Jan 9.

    Letter, Reply:

    Response.

    • Association between variants of 5-hydroxytryptamine receptor 3C (HTR3C) and chemotherapy-induced symptoms in women receiving adjuvant treatment for breast cancer.
    • Pud D, Har-Zahav G, Laitman Y, Rubinek T, Yeheskel A, Ben-Ami S, Kaufman B, Friedman E, Symon Z, Wolf I.
    • Breast Cancer Res Treat. 2014 Feb;144(1):123-31. doi: 10.1007/s10549-014-2832-y. Epub 2014 Jan 30.
    • Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer.
    • Brewer NT, Defrank JT, Chiu WK, Ibrahim JG, Walko CM, Rubin P, Olajide OA, Moore SG, Raab RE, Carrizosa DR, Corso SW, Schwartz G, Peppercorn JM, McLeod HL, Carey LA, Irvin WJ Jr.
    • Public Health Genomics. [2014 Feb;]17(1):43-7. doi: 10.1159/000356565. Epub 2014 Jan 22.
    • Evaluation of ultra-deep targeted sequencing for personalized breast cancer care.
    • Harismendy O, Schwab RB, Alakus H, Yost SE, Matsui H, Hasteh F, Wallace AM, Park HL, Madlensky L, Parker B, Carpenter PM, Jepsen K, Anton-Culver H, Frazer KA.
    • Breast Cancer Res. 2013 Dec 10;15(6):R115. doi: 10.1186/bcr3584.
    • Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
    • Ruddy KJ, Desantis SD, Gelman RS, Wu AH, Punglia RS, Mayer EL, Tolaney SM, Winer EP, Partridge AH, Burstein HJ.
    • Breast Cancer Res Treat. 2013 Oct;141(3):421-7. doi: 10.1007/s10549-013-2700-1. Epub 2013 Sep 24.
    • Germline and somatic mutations in homologous recombination genes predict platinum response and improved overall survival in ovarian, fallopian tube, and peritoneal carcinomas.
    • Pennington K, Walsh T, Harrell M, Lee M, Pennil C, Casadei S, Agnew K, Garcia R, Rendi M, King M, Swisher E.
    • Gynecologic Oncology. 2013 Oct;131(1):257-8. doi: 10.1016/j.ygyno.2013.07.028.
    • Conference abstract
    • CYP2D6 genotyping and the use of tamoxifen in breast cancer.
    • Berry D.
    • J Natl Cancer Inst. 2013 Sep 4;105(17):1267-9. doi: 10.1093/jnci/djt221. Epub 2013 Aug 19.

    See PubMed abstract for multiple related items.

    • Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.
    • Rae JM, Regan MM, Thibert JN, Gersch C, Thomas D, Leyland-Jones B, Viale G, Pusztai L, Hayes DF, Skaar T, Van Poznak C.
    • J Natl Cancer Inst. 2013 Sep 4;105(17):1332-4. doi: 10.1093/jnci/djt204. Epub 2013 Aug 19.

    See PubMed abstract for multiple related items.

    • Clinical effects of A4889G and T6235C polymorphisms in cytochrome P-450 CYP1A1 for breast cancer patients treated with tamoxifen: implications for tumor aggressiveness and patient survival.
    • Cardoso-Filho C, Sarian LO, de Oliveira CB, da Silveira Bossi L, Lourenço GJ, Lima CS, Gurgel MS.
    • Cancer Chemother Pharmacol. 2013 Sep;72(3):529-35. doi: 10.1007/s00280-013-2221-y. Epub 2013 Jul 11.
    • Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.
    • Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, Hays JL, Kohn EC.
    • Br J Cancer. 2013 Aug 20;109(4):1072-8. doi: 10.1038/bjc.2013.389. Epub 2013 Jul 18.
    • Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention.
    • Ingle JN, Liu M, Wickerham DL, Schaid DJ, Wang L, Mushiroda T, Kubo M, Costantino JP, Vogel VG, Paik S, Goetz MP, Ames MM, Jenkins GD, Batzler A, Carlson EE, Flockhart DA, Wolmark N, Nakamura Y, Weinshilboum RM.
    • Cancer Discov. 2013 Jul;3(7):812-25. doi: 10.1158/2159-8290.CD-13-0038. Epub 2013 Jun 13.
    • Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways.
    • Galic V, Coleman RL, Herzog TJ.
    • Curr Cancer Drug Targets. 2013 Jul;13(6):698-707.
    • Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
    • Vulsteke C, Lambrechts D, Dieudonné A, Hatse S, Brouwers B, van Brussel T, Neven P, Belmans A, Schöffski P, Paridaens R, Wildiers H.
    • Ann Oncol. 2013 Jun;24(6):1513-25. doi: 10.1093/annonc/mdt008. Epub 2013 Feb 7.
    • CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.
    • Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Hauptmann M, van Schaik RH, Berns EM, Vermorken JB, van Diest PJ, Linn SC.
    • Breast Cancer Res Treat. 2013 Jun;139(3):649-55. doi: 10.1007/s10549-013-2568-0. Epub 2013 Jun 5.
    • Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial.
    • Roca L, Diéras V, Roché H, Lappartient E, Kerbrat P, Cany L, Chieze S, Canon JL, Spielmann M, Penault-Llorca F, Martin AL, Mesleard C, Lemonnier J, de Cremoux P.
    • Breast Cancer Res Treat. 2013 Jun;139(3):789-800. doi: 10.1007/s10549-013-2587-x. Epub 2013 Jun 19.
    • Pharmacogenomics of endocrine therapy in breast cancer.
    • Ingle JN.
    • J Hum Genet. 2013 Jun;58(6):306-312. doi: 10.1038/jhg.2013.35. Epub 2013 May 2.
    • Breast Cancer Patients' Views on the Use of Genomic Testing to Guide Decisions about Their Postoperative Chemotherapy.
    • Seror V, Marino P, Bertucci F, Mancini J, Extra JM, Ferrero JM, Bachelot T, Viens P, Julian-Reynier C.
    • Public Health Genomics. [2013 May;]16(3):110-7. doi: 10.1159/000349920. Epub 2013 Apr 6.
    • Lipid metabolism genes in contralateral unaffected breast and estrogen receptor status of breast cancer.
    • Wang J, Scholtens D, Holko M, Ivancic D, Lee O, Hu H, Chatterton RT Jr, Sullivan ME, Hansen N, Bethke K, Zalles CM, Khan SA.
    • Cancer Prev Res (Phila). 2013 Apr;6(4):321-30. doi: 10.1158/1940-6207.CAPR-12-0304. Epub 2013 Mar 19.

    Press: Breast cancer gene test could allow preventive treatment. (The Telegraph)

    • Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer.
    • Przybylowska-Sygut K, Stanczyk M, Kusinska R, Kordek R, Majsterek I.
    • Clin Breast Cancer. 2013 Feb;13(1):61-8. doi: 10.1016/j.clbc.2012.09.019. Epub 2012 Oct 26.
    • Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.
    • Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M.
    • J Clin Oncol. 2013 Jan 10;31(2):176-80. doi: 10.1200/JCO.2012.44.6625. Epub 2012 Oct 22.

    See PubMed abstract for multiple related items.

    • Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment.
    • Li J, Czene K, Brauch H, Schroth W, Saladores P, Li Y, Humphreys K, Hall P.
    • Breast Cancer Res. 2013;15(5):R93.
    • Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study.
    • Brooks JD, Teraoka SN, Malone KE, Haile RW, Bernstein L, Lynch CF, Mellemkjær L, Duggan DJ, Reiner AS, Concannon P, Schiermeyer K, Lewinger JP; WECARE Study Collaborative Group, Bernstein JL, Figueiredo JC.
    • Int J Mol Epidemiol Genet. 2013;4(1):35-48. Epub 2013 Mar 18.
    • Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy.
    • Lyon E, Gastier Foster J, Palomaki GE, Pratt VM, Reynolds K, Sábato MF, Scott SA, Vitazka P.
    • Genet Med. 2012 Dec;14(12):990-1000. doi: 10.1038/gim.2012.108. Epub 2012 Sep 6.
    • Breast cancer in the Arctic--changes over the past decades.
    • Fredslund SO, Bonefeld-Jørgensen EC.
    • Int J Circumpolar Health. 2012 Aug 16;71:19155. doi: 10.3402/ijch.v71i0.19155.

    Review:

    Breast cancer in the Arctic--changes over the past decades.

    • Predicting breast cancer chemotherapeutic response using a novel tool for microarray data analysis.
    • Cheng J, Greshock J, Painter J, Lin X, Lee K, Zheng S, Menius A.
    • J Integr Bioinform. 2012 Aug 2;9(2):209. doi: 10.2390/biecoll-jib-2012-209.
    • BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients.
    • Cerne JZ, Zong L, Jelinek J, Hilsenbeck SG, Wang T, Oesterreich S, McGuire SE.
    • Breast Cancer Res Treat. 2012 Aug;135(1):135-43. doi: 10.1007/s10549-012-2117-2. Epub 2012 Jun 16.
    • Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.
    • Rottenberg S, Vollebergh MA, de Hoon B, de Ronde J, Schouten PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, Lodén M, Sol W, van der Burg E, Wesseling J, Gillet JP, Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers J, Borst P.
    • Cancer Res. 2012 May 1;72(9):2350-61. doi: 10.1158/0008-5472.CAN-11-4201. Epub 2012 Mar 6.
    • An interview with Pharmacogenomics for the breast cancer special focus issue.
    • Ashworth A.
    • Pharmacogenomics. 2012 Apr;13(6):651-4.
    • CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
    • Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G; Breast International Group (BIG) 1-98 Collaborative Group.
    • J Natl Cancer Inst. 2012 Mar 21;104(6):441-51. doi: 10.1093/jnci/djs125. Epub 2012 Mar 6.

    See PubMed abstract for multiple related items.

    Press: CYP2D6 Genotype Not Predictive of Tamoxifen Effectiveness. (Medscape)

    Press: Studies show that CYP2D6 genotype does not predict tamoxifen benefit. (EurekAlert!)

    • CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
    • Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M; ATAC trialists.
    • J Natl Cancer Inst. 2012 Mar 21;104(6):452-60. doi: 10.1093/jnci/djs126. Epub 2012 Mar 6.

    See PubMed abstract for multiple related items.

    Press: CYP2D6 Genotype Not Predictive of Tamoxifen Effectiveness. (Medscape)

    Press: Studies show that CYP2D6 genotype does not predict tamoxifen benefit. (EurekAlert!)

    • Effect of CYP2D6 polymorphisms on breast cancer recurrence.
    • Morrow PK, Serna R, Broglio K, Pusztai L, Nikoloff DM, Hillman GR, Fontecha M, Li R, Michaud L, Hortobagyi G, Gonzalez-Angulo AM.
    • Cancer. 2012 Mar 1;118(5):1221-7. doi: 10.1002/cncr.26407. Epub 2011 Aug 5.
    • Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
    • Fleming ND, Agadjanian H, Nassanian H, Miller CW, Orsulic S, Karlan BY, Walsh CS.
    • Cancer. 2012 Feb 1;118(3):689-97. doi: 10.1002/cncr.26329. Epub 2011 Jul 12.
    • Genetic variants in oxidative stress-related genes predict chemoresistance in primary breast cancer: a prospective observational study and validation.
    • Yu KD, Huang AJ, Fan L, Li WF, Shao ZM.
    • Cancer Res. 2012 Jan 15;72(2):408-19. doi: 10.1158/0008-5472.CAN-11-2998. Epub 2011 Dec 6.
    • Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
    • Park IH, Ro J, Park S, Lim HS, Lee KS, Kang HS, Jung SY, Lee S.
    • Breast Cancer Res Treat. 2012 Jan;131(2):455-61. doi: 10.1007/s10549-011-1425-2. Epub 2011 Mar 25.
    • Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients.
    • Kiyotani K, Mushiroda T, Imamura CK, Tanigawara Y, Hosono N, Kubo M, Sasa M, Nakamura Y, Zembutsu H.
    • Breast Cancer Res Treat. 2012 Jan;131(1):137-45. doi: 10.1007/s10549-011-1777-7. Epub 2011 Sep 23.

    Research news:

    Highlights from the latest articles in breast cancer pharmacogenomics.

    • Breast cancer in the Arctic - changes over the past decades.
    • Fredslund SO, Bonefeld-Jørgensen EC.
    • Int J Circumpolar Health. 2012 Jan;71(1):19155. doi: 10.3402/ijch.v71i0.19155.

    Review:

    Breast cancer in the Arctic--changes over the past decades.